Double award: “Top 100 Chinese Life Science Service Companies Brand 2024” and “Top 20 CROs in Clinical Operations for Drug Registration in China”
Consecutive Selection for the “2024 China Life Science Service Enterprise Brand Top 100”
ClinChoice Group has been honored with a consecutive selection for the prestigious “2024 China Life Science Service Enterprise Brand Top 100.” Leveraging its outstanding service capabilities and brand influence, ClinChoice has firmly secured this recognition once again. The ranking evaluates enterprises comprehensively based on market value (or valuation) and customer coverage, highlighting overall performance in the life sciences service sector. ClinChoice’s two-year consecutive inclusion in this esteemed list reaffirms its leadership position and broad influence within the industry.
Selected as a “Top 20 CRO for Clinical Operations in China Pharmaceutical Registration”
ClinChoice has been ranked among the Top 20 CROs for clinical operations in pharmaceutical registration, as announced by PharmaIntelligence’s latest report. This accolade recognizes ClinChoice’s remarkable achievements in clinical trials, encompassing various aspects such as trial design, execution, data analysis, and report preparation.
PharmaIntelligence evaluates the comprehensive strength of clinical CROs in China by aggregating data from different dimensions of registration clinical trials (CDE-listed clinical trials) and applying a weighted scoring system. ClinChoice excelled across several critical scoring dimensions, standing out as a top contender.
ClinChoice’s growth is built on the trust and support of its clients. The company remains steadfast in its “client-first” philosophy, continuously optimizing service processes and enhancing quality. Moreover, ClinChoice actively invests in innovation and talent development, injecting sustained momentum into the company’s long-term growth and success.
Source Link:
